nach oben

Current HIV/AIDS Reports

Erschienen in:

29.08.2018 | Central Nervous System and Cognition (S Spudich, Section Editor)

CNS Persistence of HIV-1 in Children: the Untapped Reservoir

verfasst von: Ann Chahroudi, Thor A. Wagner, Deborah Persaud

Erschienen in: Current HIV/AIDS Reports | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The central nervous system (CNS) represents a potential HIV-1 reservoir that may need to be specifically targeted by remission strategies. Perinatally HIV-1-infected children and youth are exposed to HIV-1 at a critical period of brain development. This review summarizes the current literature regarding HIV-1 and the CNS in perinatal infection.

Recent Findings

HIV-1-associated encephalopathy is prevalent with perinatal infection and neurocognitive impairment persists even following antiretroviral treatment (ART)-mediated suppression of viremia. Compartmentalization of HIV-1 between plasma and CSF of ART-naïve, perinatally infected children suggests the presence of a CNS reservoir; however, similar studies have not yet been conducted with ART suppression. CSF viral escape where CSF and plasma virus concentrations are discordant has been reported in this population, but larger studies with well-defined virologic and immunologic parameters are needed.

Summary

A better understanding of HIV-1 persistence in the CNS with perinatal infection is essential for improving long-term neurocognitive outcomes and for designing strategies to induce HIV-1 remission in this population.

UNAIDS Global AIDS Update 2016: UNAIDS 2016. Available from: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016.

Joseph SB, Arrildt KT, Sturdevant CB, Swanstrom R. HIV-1 target cells in the CNS. J Neuro-Oncol. 2015;21(3):276–89. https://doi.org/10.1007/s13365-014-0287-x.CrossRef

Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, Moss H, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988;319(14):889–96. https://doi.org/10.1056/NEJM198810063191401.CrossRefPubMed

Mirani G, Williams PL, Chernoff M, Abzug MJ, Levin MJ, Seage GR 3rd, et al. Changing trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy. Clin Infect. Dis. 2015;61(12):1850–61. https://doi.org/10.1093/cid/civ687.CrossRefPubMedPubMedCentral

Epstein LG, Sharer LR, Goudsmit J. Neurological and neuropathological features of human immunodeficiency virus infection in children. Ann Neurol. 1988;23(Suppl):S19–23.CrossRefPubMed

Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR 3rd, et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS. 2009;23(14):1893–901. https://doi.org/10.1097/QAD.0b013e32832dc041.CrossRefPubMedPubMedCentral

Brahmbhatt H, Boivin M, Ssempijja V, Kigozi G, Kagaayi J, Serwadda D, et al. Neurodevelopmental benefits of antiretroviral therapy in Ugandan children aged 0-6 years with HIV. J Acquir Immune Defic Syndr. 2014;67(3):316–22. https://doi.org/10.1097/QAI.0000000000000295.CrossRefPubMedPubMedCentral

Koekkoek S, de Sonneville LM, Wolfs TF, Licht R, Geelen SP. Neurocognitive function profile in HIV-infected school-age children. Eur J Paediatr Neurol. 2008;12(4):290–7. https://doi.org/10.1016/j.ejpn.2007.09.002.CrossRefPubMed

Puthanakit T, Ananworanich J, Vonthanak S, Kosalaraksa P, Hansudewechakul R, van der Lugt J, et al. Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J. 2013;32(5):501–8. https://doi.org/10.1097/INF.0b013e31827fb19d.CrossRefPubMedPubMedCentral

10.

Smith R, Chernoff M, Williams PL, Malee KM, Sirois PA, Kammerer B, et al. Impact of HIV severity on cognitive and adaptive functioning during childhood and adolescence. Pediatr Infect Dis J. 2012;31(6):592–8. https://doi.org/10.1097/INF.0b013e318253844b.CrossRefPubMed

11.

Tamula MA, Wolters PL, Walsek C, Zeichner S, Civitello L. Cognitive decline with immunologic and virologic stability in four children with human immunodeficiency virus disease. Pediatrics. 2003;112(3 Pt 1):679–84.CrossRefPubMed

12.

Wood SM, Shah SS, Steenhoff AP, Rutstein RM. The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. AIDS. 2009;23(14):1859–65. https://doi.org/10.1097/QAD.0b013e32832d924f.CrossRefPubMed

13.

Ruel TD, Boivin MJ, Boal HE, Bangirana P, Charlebois E, Havlir DV, et al. Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin. Infect. Dis. 2012;54(7):1001–9. https://doi.org/10.1093/cid/cir1037.CrossRefPubMedPubMedCentral

14.

Laughton B, Cornell M, Grove D, Kidd M, Springer PE, Dobbels E, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS. 2012;26(13):1685–90. https://doi.org/10.1097/QAD.0b013e328355d0ce.CrossRefPubMedPubMedCentral

15.

Crowell CS, Huo Y, Tassiopoulos K, Malee KM, Yogev R, Hazra R, et al. Early viral suppression improves neurocognitive outcomes in HIV-infected children. AIDS. 2015;29(3):295–304. https://doi.org/10.1097/QAD.0000000000000528.CrossRefPubMedPubMedCentral

16.

Sarma MK, Nagarajan R, Keller MA, Kumar R, Nielsen-Saines K, Michalik DE, et al. Regional brain gray and white matter changes in perinatally HIV-infected adolescents. Neuroimage Clin. 2014;4:29–34. https://doi.org/10.1016/j.nicl.2013.10.012.CrossRefPubMed

17.

Herting MM, Uban KA, Williams PL, Gautam P, Huo Y, Malee K, et al. Default mode connectivity in youth with perinatally acquired HIV. Medicine (Baltimore). 2015;94(37):e1417. https://doi.org/10.1097/MD.0000000000001417.CrossRef

18.

Uban KA, Herting MM, Williams PL, Ajmera T, Gautam P, Huo Y, et al. White matter microstructure among youth with perinatally acquired HIV is associated with disease severity. AIDS. 2015;29(9):1035–44. https://doi.org/10.1097/QAD.0000000000000648.CrossRefPubMedPubMedCentral

19.

Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS. 2014;9(6):552–8. https://doi.org/10.1097/COH.0000000000000108.CrossRefPubMedPubMedCentral

20.

Kaleita TA. Central nervous system-directed therapy in the treatment of childhood acute lymphoblastic leukemia and studies of neurobehavioral outcome: Children’s Cancer Group trials. Curr Oncol Rep. 2002;4(2):131–41.CrossRefPubMed

21.

Swanstrom R. CNS as an HIV Reservoir. Boston: CROI; 2016.

22.

Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 2011;7(10):e1002286. https://doi.org/10.1371/journal.ppat.1002286.CrossRefPubMedPubMedCentral

23.

Tong CY, Costelloe S, Hubb J, Mullen J, O’Shea S, Marta M, et al. Deep sequencing of HIV-1 in cerebrospinal fluid. Clin. Infect. Dis. 2015;61(6):1022–5. https://doi.org/10.1093/cid/civ417.CrossRefPubMed

24.

Gianella S, Kosakovsky Pond SL, Oliveira MF, Scheffler K, Strain MC, De la Torre A, et al. Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy. Virus Evolution. 2016;2(2):vew020. https://doi.org/10.1093/ve/vew020.CrossRefPubMedPubMedCentral

25.

Dahl V, Gisslen M, Hagberg L, Peterson J, Shao W, Spudich S, et al. An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis. 2014;209(10):1618–22. https://doi.org/10.1093/infdis/jit805.CrossRefPubMed

26.

Sturdevant CB, Dow A, Jabara CB, Joseph SB, Schnell G, Takamune N, et al. Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children. PLoS Pathog. 2012;8(12):e1003094. https://doi.org/10.1371/journal.ppat.1003094.CrossRefPubMedPubMedCentral

27.

Ferretti F, Gisslen M, Cinque P, Price RW. Cerebrospinal fluid HIV escape from antiretroviral therapy. Curr HIV/AIDS Rep. 2015;12(2):280–8. https://doi.org/10.1007/s11904-015-0267-7.CrossRefPubMed

28.

Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol. 1997;42(5):679–88. https://doi.org/10.1002/ana.410420503.CrossRefPubMed

29.

de Oliveira MF, Gianella S, Letendre S, Scheffler K, Kosakovsky Pond SL, Smith DM, et al. Comparative analysis of cell-associated HIV DNA levels in cerebrospinal fluid and peripheral blood by droplet digital PCR. PLoS One. 2015;10(10):e0139510. https://doi.org/10.1371/journal.pone.0139510.CrossRefPubMedPubMedCentral

30.

Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS Pathog. 2015;11(3):e1004720. https://doi.org/10.1371/journal.ppat.1004720.CrossRefPubMedPubMedCentral

31.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin. Infect. Dis. 2010;50(5):773–8. https://doi.org/10.1086/650538.CrossRefPubMed

32.

Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26(14):1765–74. https://doi.org/10.1097/QAD.0b013e328355e6b2.CrossRefPubMed

33.

Tiraboschi JM, Munoz-Moreno JA, Puertas MC, Alonso-Villaverde C, Prats A, Ferrer E, et al. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch. HIV medicine. 2015;16(6):388–92. https://doi.org/10.1111/hiv.12243.CrossRefPubMed

34.

Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12):1819–25. https://doi.org/10.1086/657342.CrossRefPubMedPubMedCentral

35.

Perez Valero I, Letendre S, Ellis RD, Deutsch R, Franklin D, Clifford D, Heaton R, McCutchan J, McArthur J, Morgello S, Gelman B, Collier A, Grant I. Prevalence and risk factors for HIV CSF Viral Escape: Results from the CHARTER and HNRP cohorts. Oral abstract O334: Journal of International AIDS Society. 2012;15(Supplement 4).

36.

Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. J Inf Secur. 2012;65(3):239–45. https://doi.org/10.1016/j.jinf.2012.04.007.CrossRef

37.

Santos JR, Munoz-Moreno JA, Molto J, Prats A, Curran A, Domingo P, et al. Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. PLoS One. 2013;8(7):e70201. https://doi.org/10.1371/journal.pone.0070201.CrossRefPubMedPubMedCentral

38.

Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014;28(15):2251–8. https://doi.org/10.1097/QAD.0000000000000400.CrossRefPubMedPubMedCentral

39.

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13(11):1139–51. https://doi.org/10.1016/S1474-4422(14)70137-1.CrossRefPubMedPubMedCentral

40.

Eden A, Nilsson S, Hagberg L, Fuchs D, Zetterberg H, Svennerholm B, et al. Asymptomatic cerebrospinal fluid HIV-1 viral blips and viral escape during antiretroviral therapy: a longitudinal study. J Infect Dis. 2016;214(12):1822–5. https://doi.org/10.1093/infdis/jiw454.CrossRefPubMed

41.

van Arnhem LA, Bunders MJ, Scherpbier HJ, Majoie CB, Reneman L, Frinking O, et al. Neurologic abnormalities in HIV-1 infected children in the era of combination antiretroviral therapy. PLoS One. 2013;8(5):e64398. https://doi.org/10.1371/journal.pone.0064398.CrossRefPubMedPubMedCentral

42.

Joseph J, Cinque P, Colosi D, Dravid A, Ene L, Fox H, et al. Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD. USA J Virus Erad. 2016;2(4):243–50.PubMed

43.

Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D. Neopterin in HIV-1 infection. Mol Immunol. 2005;42(2):183–94. https://doi.org/10.1016/j.molimm.2004.06.017.CrossRefPubMed

44.

Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(2):168–73. https://doi.org/10.1097/QAI.0b013e31815ace97.CrossRefPubMedPubMedCentral

45.

Eden A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D, et al. Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PLoS One. 2016;11(6):e0157160. https://doi.org/10.1371/journal.pone.0157160.CrossRefPubMedPubMedCentral

46.

Yuan L, Qiao L, Wei F, Yin J, Liu L, Ji Y, et al. Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China. J Neurovirol. 2013;19(2):144–9. https://doi.org/10.1007/s13365-013-0150-5.CrossRefPubMedPubMedCentral

47.

McCoig C, Castrejon MM, Saavedra-Lozano J, Castano E, Baez C, Lanier ER, et al. Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004;23(2):114–8. https://doi.org/10.1097/01.inf.0000109247.67480.7a.CrossRefPubMed

48.

Gisslen M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135–40. https://doi.org/10.1016/j.ebiom.2015.11.036.CrossRefPubMed

49.

McGuire JL, Gill AJ, Douglas SD, Kolson DL, group CHA-RTER. Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders. J Neuro-Oncol. 2015;21(4):439–48. https://doi.org/10.1007/s13365-015-0333-3.CrossRef

50.

Jessen Krut J, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014;9(2):e88591. https://doi.org/10.1371/journal.pone.0088591.CrossRefPubMedPubMedCentral

51.

Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS. 2013;27(9):1387–95. https://doi.org/10.1097/QAD.0b013e32836010bd.CrossRefPubMed

52.

Ananworanich J, Kerr SJ, Jaimulwong T, Vibol U, Hansudewechakul R, Kosalaraksa P, et al. Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children. J Virus Erad. 2015;1(3):196–202.PubMedPubMedCentral

53.

Kapetanovic S, Griner R, Zeldow B, Nichols S, Leister E, Gelbard HA, et al. Biomarkers and neurodevelopment in perinatally HIV-infected or exposed youth: a structural equation model analysis. AIDS. 2014;28(3):355–64. https://doi.org/10.1097/QAD.0000000000000072.CrossRefPubMedPubMedCentral

54.

Eckard AR, Rosebush JC, O’Riordan MA, Graves CC, Alexander A, Grover AK, et al. Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation. Antivir Ther. 2017;22:669–80. https://doi.org/10.3851/IMP3157.CrossRefPubMedPubMedCentral

Titel: CNS Persistence of HIV-1 in Children: the Untapped Reservoir
verfasst von: Ann Chahroudi
Thor A. Wagner
Deborah Persaud
Publikationsdatum: 29.08.2018
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 5/2018
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-018-0412-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen